Wuhan Changlian Laifu Pharmaceutical

Wuhan Changlian Laifu Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, manufacturing, and commercialization of chemical generic drugs. Established in 2004 and headquartered in Wuhan, Hubei Province, the company focuses primarily on therapeutic areas such as anti-infectives, cardiovascular diseases, and digestive system disorders. Its core product portfolio features freeze-dried powder injections and small-volume injections, including key products like Sodium Aescinate for Injection, Ganciclovir for Injection, Acyclovir for Injection, and Azithromycin for Injection. The company operates advanced GMP-certified manufacturing facilities and has expanded its production footprint through subsidiaries like Hubei Changlian Dule Pharmaceutical. Wuhan Changlian Laifu Pharmaceutical is publicly traded on the National Equities Exchange and Quotations (NEEQ) under the ticker 834239.